MedTrace Logo

Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)

NCT00211354 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2009-02-04

No results posted yet for this study

Summary

Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina. Complications of retinal vein occlusion which threaten vision include neovascularization(growth of new blood vessels)and macular edema ( accumulation of fluid "leaking" from abnormal blood vessels). Currently, the treatment of retinal vein occlusion is laser photocoagulation. This treatment has found to have limited use in this type of condition.Anecortave Acetate is being considered as an attempt to control the growth of the abnormal blood vessels.

Conditions

  • Retinal Vein Occlusion

Interventions

DRUG

Anecortave Acetate

ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Manhattan Eye, Ear & Throat Hospital

    lead OTHER

Principal Investigators

  • Lawrence A. Yannuzzi, MD · Manhattan Eye, Ear & Throat Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2007-03-31
Completion
2007-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00211354 on ClinicalTrials.gov